Show simple item record

dc.contributor.authorGiustina, A
dc.contributor.authorBronstein, M D
dc.contributor.authorCasanueva, F F
dc.contributor.authorChanson, P
dc.contributor.authorGhigo, E
dc.contributor.authorHo, K K Y
dc.contributor.authorKlibanski, A
dc.contributor.authorLamberts, S
dc.contributor.authorTrainer, Peter J
dc.contributor.authorMelmed, S
dc.date.accessioned2011-12-28T17:18:54Z
dc.date.available2011-12-28T17:18:54Z
dc.date.issued2011-06
dc.identifier.citationCurrent management practices for acromegaly: an international survey. 2011, 14 (2):125-33 Pituitaryen
dc.identifier.issn1573-7403
dc.identifier.pmid21063787
dc.identifier.doi10.1007/s11102-010-0269-9
dc.identifier.urihttp://hdl.handle.net/10541/199111
dc.description.abstractTo determine whether peer-reviewed consensus statements have changed clinical practice, we surveyed acromegaly care in specialist centers across the globe, and determined the degree of adherence to published consensus guidelines on acromegaly management. Sixty-five acromegaly experts who participated in the 7th Acromegaly Consensus Workshop in March 2009 responded. Results indicated that the most common referring sources for acromegaly patients were other endocrinologists (in 26% of centers), neurosurgeons (25%) and primary care physicians (21%). In sixty-nine percent of patients, biochemical diagnoses were made by evaluating results of a combination of growth hormone (GH) nadir/basal GH and elevated insulin like growth factor-I (IGF-I) levels. In both Europe and the USA, neurosurgery was the treatment of choice for GH-secreting microadenomas and for macroadenomas with compromised visual function. The most widely used criteria for neurosurgical outcome assessment were combined measurements of IGF-I and GH levels after oral glucose tolerance test (OGTT) 3 months after surgery. Ninety-eight percent of respondents stated that primary treatment with somatostatin receptor ligands (SRLs) was indicated at least sometime during the management of acromegaly patients. In nearly all centers (96%), the use of pegvisomant monotherapy was restricted to patients who had failed to achieve biochemical control with SRL therapy. The observation that most centers followed consensus statement recommendations encourages the future utility of these workshops aimed to create uniform management standards for acromegaly.
dc.language.isoenen
dc.subject.meshAcromegaly
dc.subject.meshAustralia
dc.subject.meshBrazil
dc.subject.meshCanada
dc.subject.meshChina
dc.subject.meshData Collection
dc.subject.meshEndocrinology
dc.subject.meshEurope
dc.subject.meshHumans
dc.subject.meshInternationality
dc.subject.meshNeurosurgery
dc.subject.meshNew Zealand
dc.subject.meshPhysicians, Primary Care
dc.subject.meshPostoperative Period
dc.subject.meshProfessional Practice
dc.subject.meshTreatment Outcome
dc.subject.meshUnited States
dc.titleCurrent management practices for acromegaly: an international survey.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical and Surgical Sciences, University of Brescia, Endocrine Service, Montichiari Hospital, Via Ciotti 154, 25018 Montichiari, Italy.en
dc.identifier.journalPituitaryen
html.description.abstractTo determine whether peer-reviewed consensus statements have changed clinical practice, we surveyed acromegaly care in specialist centers across the globe, and determined the degree of adherence to published consensus guidelines on acromegaly management. Sixty-five acromegaly experts who participated in the 7th Acromegaly Consensus Workshop in March 2009 responded. Results indicated that the most common referring sources for acromegaly patients were other endocrinologists (in 26% of centers), neurosurgeons (25%) and primary care physicians (21%). In sixty-nine percent of patients, biochemical diagnoses were made by evaluating results of a combination of growth hormone (GH) nadir/basal GH and elevated insulin like growth factor-I (IGF-I) levels. In both Europe and the USA, neurosurgery was the treatment of choice for GH-secreting microadenomas and for macroadenomas with compromised visual function. The most widely used criteria for neurosurgical outcome assessment were combined measurements of IGF-I and GH levels after oral glucose tolerance test (OGTT) 3 months after surgery. Ninety-eight percent of respondents stated that primary treatment with somatostatin receptor ligands (SRLs) was indicated at least sometime during the management of acromegaly patients. In nearly all centers (96%), the use of pegvisomant monotherapy was restricted to patients who had failed to achieve biochemical control with SRL therapy. The observation that most centers followed consensus statement recommendations encourages the future utility of these workshops aimed to create uniform management standards for acromegaly.


This item appears in the following Collection(s)

Show simple item record